Thursday, July 31, 2014

Merck Vs. Pfizer Nanomedicines Efforts Featured, In New Story

Overall slow Whitehouse Station news day (these, being the dog days of summer) -- so I'll drop this one in. [My February 2014 backgrounder here.]

I think it is good, insofar as it goes. Sort of superficial, but accurate. Do go read it all, at Bidness.etc, online:

. . . .Pfizer:

Pfizer, the biggest drug maker in the world, signed a deal with BIND Therapeutics Inc. (BIND) last year, to collaborate on the development of nanoparticles, called Accurins. The particles are capable of highly selective targeted and programmable nano-based therapeutics effective for oncology, inflammatory diseases and cardiovascular disorders.

Both the companies will collaborate on the preclinical research of Accurins. The deal, which was signed on April 2013, made Bind eligible for an upfront payment of $50 million, while $160 million is tied to the regulatory and sales milestone.

Pfizer has been spending over $6 billion on R&D for over a decade, and had 279 R&D projects going on by the end of 2013. Among those, 20 were in phase 3, while all others were in earlier stages of testing.


Merck is one of the biggest supporters of nanotechnology. Some of its major products with nanotechnology intervention include anti-nausea drug Emend, animal health product Panacur, and sunscreen line Coppertone [Ed. Note: that last one is being divested, to Bayer].

The company has signed partnership deals with Ablynx NV, Celgene Corporation and Qlight Nanotech Ltd. among others to build advanced nanomedical capabilities. This year, the company signed a deal with NanoBio Corporation, which gave it the rights to nanoemulsion (NE) adjuvant technology, which will be used in intranasal respiratory syncytial virus (RSV) and an intranasal seasonal influenza vaccine. . . .

So it goes -- glorious day here, today. . . so do go be excellent to one another!

No comments: